Mexican Health Agency Issues Alert Over Counterfeit Diabetes Medication

Mexico City — Mexico’s Federal Commission for the Protection against Sanitary Risks (Cofepris) has issued a public alert about counterfeit versions of the diabetes medication Rybelsus in 3mg, 7mg, and 14mg doses.

The warning follows an analysis presented by Novo Nordisk Mexico, the product’s registered manufacturer, which detected irregular marketing of the drug.

Authorities said these counterfeit products pose health risks because their manufacturing, storage, and transportation conditions are unknown, meaning they cannot guarantee safety or effectiveness.

Cofepris advised consumers not to purchase or use this medication from markets, street vendors, digital platforms, or unauthorized websites to avoid potential health damage.

The agency also urged people to report irregular sales and any adverse reactions through the pharmacovigilance system to prevent further distribution.

Finally, Cofepris called on pharmacies and distributors to purchase only from authorized suppliers and verify documentation while maintaining surveillance to prevent health risks.